Saniona AB Cash Flow Conversion Efficiency
Saniona AB cash flow conversion efficiency. Based on the latest financial reports, Saniona AB (SANION) has a cash flow conversion efficiency ratio of -0.125x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-79.51 Million ≈ $-8.56 Million USD) by net assets (Skr635.16 Million ≈ $68.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Saniona AB (2013–2025)
Cash flow conversion efficiency of Saniona AB from 2013 to 2025. This chart illustrates how Saniona AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Saniona AB stock price today for real-time trading data and today's change.
Saniona AB Cash Flow Conversion Ratio Explained
Saniona AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Saniona AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Saniona AB ranked by their cash flow conversion efficiency. Also see Saniona AB (SANION) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
|
0.053x |
|
Mayfair Gold Corp
V:MFG
|
-0.176x |
|
Tachan Securities Co Ltd
TWO:6020
|
-0.043x |
|
Wellgistics Health, Inc. Common Stock
NASDAQ:WGRX
|
0.227x |
|
Deep Fission, Inc. Common Stock
NASDAQ:FISN
|
-0.288x |
|
Ordinary Fully Paid Deferred Settlement
AU:BTRDA
|
N/A |
|
Orvana Minerals Corp.
TO:ORV
|
0.525x |
|
Intellego Technologies AB
ST:INT
|
0.791x |
Annual Cash Flow Conversion Efficiency for Saniona AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of Saniona AB from 2013 to 2025. Review SANION cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr635.16 Million ≈ $68.35 Million |
Skr273.86 Million ≈ $29.47 Million |
0.431x | -59.89% |
| 2024-12-31 | Skr231.82 Million ≈ $24.95 Million |
Skr249.20 Million ≈ $26.82 Million |
1.075x | -72.43% |
| 2023-12-31 | Skr-21.94 Million ≈ $-2.36 Million |
Skr-85.53 Million ≈ $-9.20 Million |
3.898x | +172.98% |
| 2022-12-31 | Skr52.71 Million ≈ $5.67 Million |
Skr-281.54 Million ≈ $-30.30 Million |
-5.341x | -336.56% |
| 2021-12-31 | Skr282.00 Million ≈ $30.35 Million |
Skr-345.04 Million ≈ $-37.13 Million |
-1.224x | -322.61% |
| 2020-12-31 | Skr603.46 Million ≈ $64.94 Million |
Skr-174.71 Million ≈ $-18.80 Million |
-0.290x | +82.82% |
| 2019-12-31 | Skr58.44 Million ≈ $6.29 Million |
Skr-98.47 Million ≈ $-10.60 Million |
-1.685x | -190.08% |
| 2018-12-31 | Skr39.46 Million ≈ $4.25 Million |
Skr-22.92 Million ≈ $-2.47 Million |
-0.581x | +61.88% |
| 2017-12-31 | Skr37.63 Million ≈ $4.05 Million |
Skr-57.34 Million ≈ $-6.17 Million |
-1.524x | -1139.50% |
| 2016-12-31 | Skr54.25 Million ≈ $5.84 Million |
Skr7.95 Million ≈ $855.87K |
0.147x | +126.93% |
| 2015-12-31 | Skr52.94 Million ≈ $5.70 Million |
Skr-28.82 Million ≈ $-3.10 Million |
-0.544x | +39.93% |
| 2014-12-31 | Skr8.78 Million ≈ $944.98K |
Skr-7.96 Million ≈ $-856.41K |
-0.906x | +86.10% |
| 2013-12-31 | Skr575.00K ≈ $61.88K |
Skr-3.75 Million ≈ $-403.34K |
-6.518x | -- |
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more